Contrasting Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO)

Genocea Biosciences (NASDAQ:GNCA) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Insider and Institutional Ownership

0.6% of Genocea Biosciences shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.6% of Genocea Biosciences shares are held by company insiders. Comparatively, 40.5% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Genocea Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.19, suggesting that its share price is 119% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Genocea Biosciences and OKYO Pharma, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genocea Biosciences	0	0	0	0	0.00
OKYO Pharma	0	0	1	0	3.00

OKYO Pharma has a consensus price target of $7.00, indicating a potential upside of 554.21%. Given OKYO Pharma’s stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Genocea Biosciences.

Profitability

This table compares Genocea Biosciences and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Genocea Biosciences	N/A	-182.88%	-62.76%
OKYO Pharma	N/A	N/A	N/A

Earnings & Valuation

This table compares Genocea Biosciences and OKYO Pharma”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genocea Biosciences	$1.91 million	0.00	-$33.20 million	($0.61)	N/A
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A

OKYO Pharma has lower revenue, but higher earnings than Genocea Biosciences.

Summary

OKYO Pharma beats Genocea Biosciences on 8 of the 10 factors compared between the two stocks.

About Genocea Biosciences

Genocea Biosciences, Inc., a biopharmaceutical company, discovers and develops novel cancer immunotherapies. The company uses its proprietary discovery platform, ATLAS, which profiles each patient's CD4+ and CD8+ T cell immune responses to every target or antigen identified by next-generation sequencing of that patient's tumor. Its products include GEN-011, an adoptive T cell therapy, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and GEN-009, a neoantigen vaccine candidate, which is in Phase 1/2a clinical trials that delivers adjuvanted synthetic long peptides spanning ATLAS-identified anti-tumor neoantigens. The company was incorporated in 2006 and is based in Cambridge, Massachusetts. On July 5, 2022, Genocea Biosciences, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Massachusetts.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.